These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38305755)

  • 41. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Nuvvula S; Dahiya S; Patel SA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
    Sam J; Hofer T; Kuettel C; Claus C; Thom J; Herter S; Georges G; Korfi K; Lechmann M; Eigenmann MJ; Marbach D; Jamois C; Lechner K; Krishnan SM; Gaillard B; Marinho J; Kronenberg S; Kunz L; Wilson S; Briner S; Gebhardt S; Varol A; Appelt B; Nicolini V; Speziale D; Bez M; Bommer E; Eckmann J; Hage C; Limani F; Jenni S; Schoenle A; Le Clech M; Vallier JP; Colombetti S; Bacac M; Gasser S; Klein C; Umaña P
    Blood; 2024 May; 143(21):2152-2165. PubMed ID: 38437725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
    Cremasco F; Menietti E; Speziale D; Sam J; Sammicheli S; Richard M; Varol A; Klein C; Umana P; Bacac M; Colombetti S; Perro M
    PLoS One; 2021; 16(1):e0241091. PubMed ID: 33406104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.
    Bukhari A; Lee ST
    Expert Rev Hematol; 2019 Nov; 12(11):909-918. PubMed ID: 31583919
    [No Abstract]   [Full Text] [Related]  

  • 47. Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.
    Sun H; Xing H; Han L; Song Y; Jiang Z; Liu Y; Yu J
    Expert Opin Biol Ther; 2024 May; 24(5):321-326. PubMed ID: 38717336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigational drugs for the treatment of diffuse large B-cell lymphoma.
    Patriarca A; Gaidano G
    Expert Opin Investig Drugs; 2021 Jan; 30(1):25-38. PubMed ID: 33295827
    [No Abstract]   [Full Text] [Related]  

  • 49. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
    Varma G; Wang J; Diefenbach C
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
    Djebli N; Parrott N; Jaminion F; O'Jeanson A; Guerini E; Carlile D
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):396-409. PubMed ID: 38044486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
    Sylvain C
    Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The evolving therapy of DLBCL: Bispecific antibodies.
    Hutchings M
    Hematol Oncol; 2023 Jun; 41(S1):107-111. PubMed ID: 37294965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
    Messori A; Rivano M; Mengato D; Chiumente M
    Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
    Frances N; Bacac M; Bray-French K; Christen F; Hinton H; Husar E; Quackenbush E; Schäfer M; Schick E; Vyver AV; Richter WF
    J Pharm Sci; 2022 Apr; 111(4):1208-1218. PubMed ID: 34953862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.